Fibrocell Science

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

Exton, US
Size (employees)
52 (est)
Fibrocell Science is headquartered in Exton, US

Key People at Fibrocell Science

Robert S. Langer

Robert S. Langer

John Maslowski

John Maslowski

Vice President, Scientific Affairs

Fibrocell Science Office Locations

Fibrocell Science has an office in Exton
Exton, US (HQ)
405 Eagleview Boulevard

Fibrocell Science Metrics

Fibrocell Science Financial Metrics

Revenue (2016)

$355 k

Revenue growth (2015-16), %


Gross profit

($342 k)

Gross profit margin (2016), %


Net income (2016)

($15.3 m)

Market capitalization (28-Apr-2017)

$30.9 m

Closing share price (28-Apr-2017)


Cash (31-Dec-2016)

$17.5 m
Fibrocell Science's current market capitalization is $30.9 m.
Fibrocell Science's revenue was reported to be $355 k in 2016
FY, 2013FY, 2014FY, 2015Y, 2016


$200 k$180 k$492 k$355 k

Revenue growth, %


Cost of goods sold

$722 k$697 k

Gross profit

($230 k)($342 k)

Gross profit Margin, %



($37.4 m)($26.5 m)

EBIT margin, %


Interest income

$8 k

Pre tax profit

($34.5 m)($15.3 m)

Net Income

($30.6 m)($25.7 m)($34.5 m)($15.3 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$60 m$37.5 m$29.3 m$17.5 m

Accounts Receivable


$1.2 m$1.3 m$1.2 m$513 k

Current Assets

$61.9 m$39.3 m$31 m$18 m


$1.7 m$1.6 m$1.6 m$1.5 m

Total Assets

$69 m$45.6 m$36.7 m$19.6 m

Accounts Payable

$3 m$1.1 m$499 k$440 k

Current Liabilities

$3.6 m$3.5 m$15.4 m$3 m

Additional Paid-in Capital

$167.3 m$143.1 m$161.3 m$170.4 m

Retained Earnings

($102.7 m)($112.7 m)($147.2 m)($162.6 m)

Total Equity

$64.7 m$14.2 m$7.9 m

Financial Leverage

1.1 x2.6 x2.5 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($30.6 m)($25.7 m)($34.5 m)($15.3 m)

Depreciation and Amortization

$863 k$883 k$767 k$564 k

Accounts Receivable

$54 k$12 k$9 k$12 k


($120 k)$26 k$35 k$796 k

Accounts Payable

$2 m($1.8 m)($114 k)($139 k)

Cash From Operating Activities

($20.1 m)($22.3 m)($24.1 m)($29.4 m)

Purchases of PP&E

($360 k)($242 k)($271 k)($253 k)

Cash From Investing Activities

($360 k)($242 k)($245 k)($252 k)

Dividends Paid

Cash From Financing Activities

$49.1 m$16.1 m$17.9 m

Fibrocell Science Market Value History

Fibrocell Science Online Presence

Fibrocell Science Company Life

You may also be interested in